Skip to main content
Top
Published in: Journal of General Internal Medicine 7/2021

01-07-2021 | Perspective

To Expand the Evidence Base About Harms from Tests and Treatments

Authors: Deborah Korenstein, MD, Russell Harris, MD, MPH, Adam G Elshaug, PhD, MPH, Joseph S Ross, MD, MHS, Daniel J Morgan, MD, MS, Richelle J Cooper, MD, MSHS, Hyung J Cho, MD, Jodi B Segal, MD, MPH

Published in: Journal of General Internal Medicine | Issue 7/2021

Login to get access

Abstract

Rigorous evidence about the broad range of harms that might be experienced by a patient in the course of testing and treatment is sparse. We aimed to generate recommendations for how researchers might more comprehensively evaluate potential harms of healthcare interventions, to allow clinicians and patients to better include this evidence in clinical decision-making. We propose seven domains of harms of tests and treatments that are relevant to patients: (1) physical impairment, (2) psychological distress, (3) social disruption, (4) disruption in connection to healthcare, (5) labeling, (6) financial impact, and (7) treatment burden. These domains will include a range of severity of harms and variation in timing after testing or treatment, attributable to the service itself or a resulting care cascade. Although some new measures may be needed, diverse data and tools are available to allow the assessment of harms comprehensively across these domains. We encourage researchers to evaluate harms in sub-populations, since the harms experienced may differ importantly by demographics, social determinants, presence of comorbid illness, psychological state, and other characteristics. Regulators, funders, and editors might require either assessment or reporting of harms in each domain or require justification for inclusion and exclusion of different domains.
Appendix
Available only for authorised users
Literature
1.
go back to reference Morgan DJ, Scherer LD, Korenstein D. Improving physician communication about treatment decisions: Reconsideration of “Risks vs. Benefits”. JAMA 2020 Sept 8; 324(10): 937-8. Morgan DJ, Scherer LD, Korenstein D. Improving physician communication about treatment decisions: Reconsideration of “Risks vs. Benefits”. JAMA 2020 Sept 8; 324(10): 937-8.
5.
go back to reference United States Food and Drug Adminstration. Patient-Focused Drug Development Glossary, 2018. United States Food and Drug Adminstration. Patient-Focused Drug Development Glossary, 2018.
11.
12.
go back to reference Harris RP, Sheridan SL, Lewis CL, et al. The Harms of Screening. A Proposed Taxonomy and Application to Lung Cancer Screening. JAMA Intern Med 2014; 174(2):281-5.CrossRefPubMed Harris RP, Sheridan SL, Lewis CL, et al. The Harms of Screening. A Proposed Taxonomy and Application to Lung Cancer Screening. JAMA Intern Med 2014; 174(2):281-5.CrossRefPubMed
14.
go back to reference Schiff GD, Martin SA, Eidelman DH, et al. Ten Principles for More Conservative, Care-Full Diagnosis. Annals Intern Med 2018; 169(9): 643-5. Schiff GD, Martin SA, Eidelman DH, et al. Ten Principles for More Conservative, Care-Full Diagnosis. Annals Intern Med 2018; 169(9): 643-5.
24.
go back to reference World Health Organization. The Conceptual Framework for the International Classification for Patient Safety v.11 Technical Annex 2 - Glossary of Patient Safety Concepts and References, 2009. World Health Organization. The Conceptual Framework for the International Classification for Patient Safety v.11 Technical Annex 2 - Glossary of Patient Safety Concepts and References, 2009.
Metadata
Title
To Expand the Evidence Base About Harms from Tests and Treatments
Authors
Deborah Korenstein, MD
Russell Harris, MD, MPH
Adam G Elshaug, PhD, MPH
Joseph S Ross, MD, MHS
Daniel J Morgan, MD, MS
Richelle J Cooper, MD, MSHS
Hyung J Cho, MD
Jodi B Segal, MD, MPH
Publication date
01-07-2021
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 7/2021
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-06597-9

Other articles of this Issue 7/2021

Journal of General Internal Medicine 7/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine